Treprostinil for pulmonary hypertension in newborns
Part of Genetic & congenital, Lungs & breathing clinical trials.
This study collects information on how well a medicine called treprostinil works and how safe it is for newborn babies with pulmonary hypertension (high blood pressure in the lungs). It is for babies who have already received this treatment as part of their regular care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby received at least one dose of treprostinil (a medicine given through a vein or under the skin).
- Your baby was less than 44 weeks old (since conception) when they started treprostinil.
- Your baby had or was suspected of having pulmonary hypertension (high blood pressure in the lungs) at that time.
- You give permission for your baby to be in the study.
- Your baby is covered by French social security.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether breathing in magnesium sulfate and giving sildenafil can improve breathing and lung blood vessel pressure in newborns with persistent pulmonary hypertension. It may help newborns who are having trouble oxygenating despite being on a ventilator.
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
This study looks at how well the drug Treprostinil works in people with a specific type of pulmonary hypertension (high blood pressure in the lungs). It helps researchers understand real-world results and side effects.
This trial tests if treprostinil can help people with pulmonary arterial hypertension (PAH) who are at intermediate risk. You may join if you have been diagnosed with certain types of PAH and meet specific heart and lung test results.
This trial tests whether an inhaled medication called treprostinil can improve exercise ability in people with exercise-induced pulmonary hypertension. It aims to see if the drug helps with shortness of breath during activity.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Hear when a new Persistent Pulmonary Hypertension of Newborn trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.